31, 2025 (GLOBE NEWSWIRE) -- Truvetas groundbreaking study analyzing real-world use of GLP-1 receptor agonist (GLP-1 RA) therapies in adults with overweight or obesity has published in JAMA Network Open , offering critical insights into GLP-1 discontinuation and reinitiation rates, and the roles income, adverse events, and weight changes may play
The dose escalation schedules differ between the two medications: Semaglutide Dose Escalation Weeks 14: 0.25mg weekly (initiation dose) Weeks 58: 0.5mg weekly Weeks 912: 1.0mg weekly Weeks 1316: 1.7mg weekly Week 17+: 2.4mg weekly (maintenance dose for weight loss) Tirzepatide Dose Escalation Weeks 14: 2.5mg weekly (initiation dose) Weeks 58: 5mg weekly Weeks 912: 7.5mg weekly (many patients maintain here) Weeks 1316: 10mg weekly Weeks 1720: 12.5mg weekly Week 21+: 15mg weekly (maximum dose) Not every patient needs to reach the maximum dose and at BlueWater Wellness Center, we don't escalate for the sake of it
Until the issue is resolved, commercial supplies of the product will be delayed for a certain period of time
GLP-1 weight loss medications (tirzepatide, semaglutide, or retatrutide) Monthly or weekly check-ins with our nurse practitioner Optional food plans, protein shakes, and nutrition coaching Continuous glucose monitor for real-time dietary feedback We guide you toward choices that work for your body, helping you avoid the sugar rollercoaster and better understand what fuels your energy and metabolism
Physiol Rev 87(1):315424
Other peptide options exist that might suit your skin better